Fineman, Mark S.

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 1,559

Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 1,346

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 1,177

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): A randomised, open-label study

Buse, J. B., Nauck, M., Forst, T., Sheu, W. H.-H., Shenouda, S. K., Heilmann, C. R., Hoogwerf, B. J., Gao, A., Boardman, M. K., Fineman, M., et al. (2013) · The Lancet

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 565

The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-Term Pharmacokinetic and 12-Week Dose-Ranging Studies

Buse, J. B., DeFronzo, R. A., Rosenstock, J., Kim, T., Burns, C., Skare, S., Baron, A., & Fineman, M. (2016) · Diabetes Care

Diabetes Treatment and ManagementMetabolism, Diabetes, and Cancer

Cited by 325

Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes

Hollander, P. A., Levy, P., Fineman, M. S., Maggs, D. G., Shen, L. Z., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2003) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 307

Amylin replacement with pramlintide as an adjunct to insulin therapy improves long‐term glycaemic and weight control in Type 1 diabetes mellitus: a 1‐year, randomized controlled trial

Ratner, R. E., Dickey, R., Fineman, M., Maggs, D. G., Shen, L., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2004) · Diabetic Medicine

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 307

Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes

Fehse, F., Trautmann, M., Holst, J. J., Halseth, A. E., Nanayakkara, N., Nielsen, L. L., Fineman, M. S., Kim, D. D., & Nauck, M. A. (2005) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 297

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes

Whitehouse, F., Kruger, D. F., Fineman, M., Shen, L., Ruggles, J. A., Maggs, D. G., Weyer, C., & Kolterman, O. G. (2002) · Diabetes Care

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 264

Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes

Linnebjerg, H., Park, S., Kothare, P. A., Trautmann, M. E., Mace, K., Fineman, M., Wilding, I., Nauck, M., & Horowitz, M. (2008) · Regulatory Peptides

Diabetes Treatment and ManagementGastrointestinal motility and disorders

Cited by 261

Adjunctive Therapy with the Amylin Analogue Pramlintide Leads to a Combined Improvement in Glycemic and Weight Control in Insulin-Treated Subjects with Type 2 Diabetes

Ratner, R. E., Want, L. L., Fineman, M. S., Velte, M. J., Ruggles, J. A., Gottlieb, A., Weyer, C., & Kolterman, O. G. (2002) · Diabetes Technology & Therapeutics

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 156

The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes

Fineman, M. S., Koda, J. E., Shen, L. Z., Strobel, S. A., Maggs, D. G., Weyer, C., & Kolterman, O. G. (2002) · Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 129

GLP‐1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice

Jolivalt, C. G., Fineman, M., Deacon, C. F., Carr, R. D., & Calcutt, N. A. (2011) · Diabetes, Obesity and Metabolism

Pain Mechanisms and TreatmentsNerve injury and regeneration

Cited by 87

Pharmacokinetics of an Oral Drug (Acetaminophen) Administered at Various Times in Relation to Subcutaneous Injection of Exenatide (Exendin‐4) in Healthy Subjects

Blase, E., Taylor, K., Gao, H., Wintle, M., & Fineman, M. (2005) · The Journal of Clinical Pharmacology

Pharmacogenetics and Drug MetabolismDiabetes Treatment and Management

Cited by 82

Exenatide effects on statin pharmacokinetics and lipid response

Kothare, P. A., Linnebjerg, H., Skrivanek, Z., Reddy, S., Mace, K., Pena, A., Han, J., Fineman, M., & Mitchell, M. (2007) · Int. Journal of Clinical Pharmacology and Therapeutics

Lipoproteins and Cardiovascular HealthPharmacogenetics and Drug Metabolism

Cited by 36